pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CTLA-4 · news · pharmadog
← back to CTLA-4
News · CTLA-4
22
stories
8d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
24d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
29d
ESMO: After leak, Merck and Moderna post phase 3 cancer vaccine data early
fiercebiotech
Oct 20, 26
‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses
fiercebiotech
Oct 7, 26
5 biggest venture capital raises of Q3 2026
biospace
Sep 14, 26
BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer
endpoints
Sep 14, 26
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 11, 26
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
Sep 10, 26
Encoded raises $275M series F for Dravet syndrome gene therapy
biospace
Sep 9, 26
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
Sep 9, 26
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 9, 26
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 3, 26
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
May 12, 26
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
onclive
May 7, 26
Dr Sznol on Optimal Treatment Sequencing in Melanoma
onclive
Apr 28, 26
BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
endpoints
Apr 22, 26
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
biopharma dive